Molecule's role in cancer suggests new combination therapy

Researchers at the University of Illinois at Chicago College of Medicine have found that a molecule found at elevated levels in cancer cells seems to protect them from the "cell-suicide" that is usually triggered by chemotherapy or radiation.

The study, published online in the journal on Feb. 29, suggests that two common cancer-fighting strategies may have "tremendous synergy" if used in combination, says Andrei Gartel, UIC associate professor of biochemistry and molecular genetics and medicine and principal investigator on the study.

Damage to a cell's DNA can set in motion a cascade of signals that triggers programmed cell death, or apoptosis. Radiation therapy and many target and somewhat selectively in rapidly dividing cells, making them useful in fighting cancer. But many cancer cells develop resistance over the course of treatment and block the suicide pathway.

Based on the observation that a in cancer cells called FOXM1 is elevated following , Gartel and his co-author sought to investigate whether FOXM1 might have a role in protecting cancer cells from apoptosis.

Using human cancer cells that were exposed to either chemicals or radiation to damage DNA, the researchers used a variety of techniques to decrease the levels of FOXM1 in these cells.

"We found a significant increase in DNA-damage-induced apoptosis in cells with diminished levels of FOXM1," Gartel said. The results were the same no matter what caused the DNA damage, or what method the researchers used to reduce FOXM1.

The researchers were able to show that FOXM1 short-circuits apoptosis by suppressing the activity of another protein, JNK, which otherwise stimulates cell death, and by turning up an anti-apoptosis protein called Bcl-2.

Besides the radiation and chemotherapy drugs long used in cancer treatment, a newer class of chemotherapy agents called proteasome inhibitors has been showing promise. All known proteasome inhibitors reduce levels of FOXM1, Gartel said.

By combining standard with proteasome inhibitors -- some of which are already FDA-approved for cancer treatment -- the drugs' effectiveness may be improved, he said.

Related Stories

Refusal of suicide order: Why tumor cells become resistant

Jun 23, 2008

Cells with irreparable DNA damage normally induce programmed cell death, or apoptosis. However, this mechanism often fails in tumor cells so that transformed cells are able to multiply and spread throughout the body. Scientists ...

Why cancer cells just won't die (w/ Video)

Dec 09, 2009

When cells experience DNA damage, they'll try to repair it. But if that fails, the damaged cells are supposed to self-destruct, a process called apoptosis. A cancer researcher at Robarts Research Institute at The University ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.